Safiglipron (KAI-7535 / HRS-7535)
HRS-7535 · KAI-7535 · safiglipron · Kailera / Hengrui
Daily oral small-molecule GLP-1 agonist; China Phase 3 topline with a separate global Phase 2 underway.
Selected study results
HARBOR-1 · China · primary analysisMean body-weight change from baselineBody weight decreased 9.79% · 44 weeks · Phase 3
Mean body-weight change from baseline · 44 weeks
Study focus: Weight management
Primary treatment-policy analysis; global obesity development remains Phase 2.
Adults with overweight or obesity in China, without diabetes · 180 mg once daily vs placebo · Trial N=556 · Primary treatment-policy estimand. Results & methods ↗
- Prespecified supplementary efficacy estimand · week 44The November poster reports 11.58% mean weight reduction with 180 mg versus 2.54% with placebo, assuming adherence.
- Ad hoc efficacy analysis · week 50The November poster reports 11.92% versus 2.65% with placebo. This ad hoc model is separate from the prespecified week-44 supplementary analysis.
- Earlier July 7 topline · historical estimatesThe July sponsor release reported 10.9% versus 2.5% for week-44 supplementary efficacy and 11.1% versus 2.6% for the ad hoc week-50 analysis. The November poster estimates above are a later reporting version; the primary week-44 treatment-policy result is unchanged. Follow-up source ↗
Gastrointestinal events were common at 180 mg: nausea 70.0%, vomiting 68.6%; 3.1% discontinued for adverse events. The supplementary and ad hoc analyses below are distinct from the primary endpoint.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Safety context
In HARBOR-1 at 180 mg once daily, nausea occurred in 70.0% and vomiting in 68.6%; 3.1% discontinued because of adverse events.
Mechanism at a glance
Obesity stage by formulation
Latest: HARBOR-1 Phase 3 topline reported in China; global obesity Phase 2 began in April 2026.
Next: Global Phase 2 data are expected in 2027.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
HARBOR-1 · China
Weight management556 adults with overweight or obesity in China, without diabetes; 120 or 180 mg once daily versus placebo. Primary treatment-policy endpoint at week 44; supplementary efficacy and ad hoc week-50 analyses are labeled separately.
OUTSTAND-2 · China T2D
Weight management with type 2 diabetesSeparate type 2 diabetes program; not the obesity development phase.
Phase 2 studies1 record
Global KAI-7535 obesity trial
Weight managementU.S. and Australia; initiated April 2026, with results expected in 2027.
